What is the 13F Pro Quality Score for PMN?

13F Pro ranks ProMIS Neurosciences Inc. (PMN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PMN's current score at https://13fpro.ai/research/PMN (free sign-up required for the full ranking).

Where does 13F Pro source PMN data?

All ProMIS Neurosciences Inc. fundamentals and ownership data come directly from SEC EDGAR. ProMIS Neurosciences Inc. files with the SEC under CIK 1374339. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PMN in?

ProMIS Neurosciences Inc. (PMN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PMN research updated on 13F Pro?

PMN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ProMIS Neurosciences Inc.(PMN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1374339 PMN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PMN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ProMIS Neurosciences Inc. (PMN), a Healthcare sector company. PMN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), ProMIS Neurosciences Inc. reports net income of $-8.2M, free cash flow of $-12.4M. Top institutional holders of PMN by reported 13-F value include JANUS HENDERSON GROUP PLC, Deep Track Capital,, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. PMN trades on the Nasdaq exchange and files with the SEC under CIK 1374339. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ProMIS Neurosciences Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-8.2M

Free Cash Flow

Q1 2026

$-12.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+121.0% YoY

$2.8MFY 2024

FY21 $-9.8MFY22 $-18.1MFY23 $-13.2MFY24 $2.8M

Operating Income

-18.0% YoY

$-16.8MFY 2024

FY21 $-8.3MFY22 $-23.4MFY23 $-14.3MFY24 $-16.8M

EPS (Diluted)

+345.8% YoY

$2.63FY 2024

FY21 $-1.69FY22 $-2.41FY23 $-1.07FY24 $2.63

Total Assets

+38.9% YoY

$18.9MFY 2024

FY21 $17.7MFY22 $6.9MFY23 $13.6MFY24 $18.9M

Total Debt

—FY 2024

FY21 $3.9MFY22 —FY23 $0.00FY24 —

Op. Cash Flow

-150.7% YoY

$-27.2MFY 2024

FY21 $-9.3MFY22 $-17.0MFY23 $-10.8MFY24 $-27.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$2.8M +121.0%	$-13.2M +26.9%	$-18.1M -84.5%	$-9.8M
Operating Income	$-16.8M -18.0%	$-14.3M +39.0%	$-23.4M -182.0%	$-8.3M
EPS (Diluted)	$2.63 +345.8%	$-1.07 +55.6%	$-2.41 -42.6%	$-1.69
Total Assets	$18.9M +38.9%	$13.6M +96.7%	$6.9M -61.0%	$17.7M
Total Debt	—	$0.00	—	$3.9M
Operating Cash Flow	$-27.2M -150.7%	$-10.8M +36.3%	$-17.0M -83.1%	$-9.3M

AI Insight: PMN Financial Trends

ProMIS remains pre-revenue with accelerating cash burn; operating losses widened through Q3 2025 before stabilizing in Q1 2026.

• Operating losses peaked at $12M in Q3 2025, then improved to $9M in Q1 2026—first quarterly improvement in eight quarters.

• Operating cash burn averaged $8M per quarter over the past eight quarters with no revenue generation visible.

• Equity swung from $16M (Q4 2024) to negative $1M (Q4 2025), recovering to $61M in Q1 2026—suggesting capital raise.

⚠ Operating cash burn of $12M in Q1 2026 is the worst on record—exceeds quarterly op losses, signaling runway pressure.

⚠ No revenue reported across eight quarters; company remains entirely R&D-funded with no clear commercialization timeline disclosed.

AI Insight: PMN Ratio Trends

ProMIS remains deeply unprofitable with deteriorating returns in Q1 2026, showing no clear path to profitability.

• ROE declined sharply from -5.8% in Q4 2024 to -54.3% in Q1 2026, indicating worsening losses relative to shareholder equity.

• ROA fell to -48.9% in Q1 2026 from -5.0% in Q4 2024, reflecting significant deterioration in asset utilization.

⚠ TTM ROIC at -68.1% signals sustained capital destruction; no meaningful improvement trajectory visible.

⚠ Majority of operational metrics remain unmeasured or suppressed, limiting visibility into operational trends.

Get alerted when PMN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ProMIS Neurosciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PMN

JANUS HENDERSON GROUP PLC
$16.4M1,292,757 sh
Deep Track Capital, LP
$10.6M835,655 sh
WELLINGTON MANAGEMENT GROUP LLP
$8.8M696,378 sh
Trails Edge Capital Partners, LP
$7.1M557,103 sh
Ally Bridge Group (NY) LLC
$5.3M414,219 sh
Woodline Partners LP
$5.0M395,295 sh
GREAT POINT PARTNERS LLC
$4.7M371,402 sh
Yu Fan
$4.2M329,760 sh
SPHERA FUNDS MANAGEMENT LTD.
$4.1M325,591 sh
Squadron Capital Management LLC
$4.1M324,977 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$16.4M	1,292,757
Deep Track Capital, LP	$10.6M	835,655
WELLINGTON MANAGEMENT GROUP LLP	$8.8M	696,378
Trails Edge Capital Partners, LP	$7.1M	557,103
Ally Bridge Group (NY) LLC	$5.3M	414,219
Woodline Partners LP	$5.0M	395,295
GREAT POINT PARTNERS LLC	$4.7M	371,402
Yu Fan	$4.2M	329,760
SPHERA FUNDS MANAGEMENT LTD.	$4.1M	325,591
Squadron Capital Management LLC	$4.1M	324,977

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PMN on your watchlist

Track score changes the day ProMIS Neurosciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PMN a good stock to buy?

13F Pro's AI-powered analysis of ProMIS Neurosciences Inc. (PMN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PMN are available on the PMN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PMN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PMN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ProMIS Neurosciences Inc.'s investment landscape.